Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal - 10/04/2023
Date Insider Type Main position Quantity % Market Cap.
10/04/23 Free

Executive/Senior Manager

4,00,000 0.6684%
01/02/23 Free

Chief Financial Officer

4,00,000 0.6686%
01/02/23 Free

Chief Operating Officer

4,00,000 0.6686%
Change 5-day change 1-year change 3-year change Capi.($)
-13.39%-23.18% - - 29.5L
+0.24%-1.54%+52.85%+60.31% 5.38TCr
-7.17%-4.39%+42.72%+73.70% 5.21TCr
+0.80%-6.31%+5.62%+413.12% 2.35TCr
-0.09%-0.01%-16.85%-16.17% 2.31TCr
-5.95%-2.58%+29.53%-7.67% 1.94TCr
-1.14%+0.03%+31.67%-31.21% 1.76TCr
-5.16%-7.00%+168.44%+291.24% 1.52TCr
-6.91%-5.83%+25.17%+636.97% 1.48TCr
+0.43%-1.03%+25.75%+186.18% 1.41TCr
Average -3.83%-2.62%+40.54%+178.50% 2.6TCr
Weighted average by Cap. -2.80%-2.36%+39.55%+137.89%
Logo Aravive, Inc.
Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The Company's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).
Employees
23
  1. Stock Market
  2. Stocks
  3. ARAV Stock